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Abstract Ovarian cancer, in particular epithelial ovarian
cancer (EOC), is commonly diagnosed when the tumor has
metastasized into the abdominal cavity with an accumu-
lation of ascites fluid. Combining histopathology and
genetic variations, EOC can be sub-grouped into Type-I
and Type-II tumors, of which the latter are more aggressive
and metastatic. Metastasis and chemoresistance are the key
events associated with the tumor microenvironment that
lead to a poor patient outcome. Kallikrein-related pepti-
dases (KLKs) are aberrantly expressed in EOC, in partic-
ular, in the more metastatic Type-II tumors. KLKs are a
family of 15 serine proteases that are expressed in diverse
human tissues and involved in various patho-physiological
processes. As extracellular enzymes, KLKs function in the
hydrolysis of growth factors, proteases, cell membrane
bound receptors, adhesion proteins, and cytokines initiating
intracellular signaling pathways and their downstream
events. High KLK levels are differentially associated with
the prognosis of ovarian cancer patients, suggesting that
they not only have application as biomarkers but also
function in disease progression, and therefore are potential
therapeutic targets. Recent studies have demonstrated the
function of these proteases in promoting and/or suppressing
the invasive behavior of ovarian cancer cells in metastasis
in vitro and in vivo. Both conventional cell culture methods
and three-dimensional platforms have been applied to
mimic the ovarian cancer microenvironment of patients,
such as the solid stromal matrix and ascites fluid. Here we
summarize published studies to provide an overview of our
understanding of the role of KLKs in EOC, and to lay the
foundation for future research directions.
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Introduction
Ovarian cancer represents a growing women’s health issue
worldwide [1–3]. In Australia, the risk of a female being
diagnosed with ovarian cancer is 1 in 79 [1]. While the age-
standardized incidence rate of ovarian cancer is decreasing,
the actual number of women diagnosed with ovarian cancer
in Australia is increasing and is projected to increase fur-
ther due to the ageing of the population. In the US, 22,240
new cases will be diagnosed and 14,030 women will die
from this cancer in 2013 [3]. The majority of ovarian
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cancers are classified as epithelial ovarian cancers (EOC,
*90 %) with the patients’ mean age at 62 years. Given the
lack of early warning signs and the lack of effective
screening, three quarters of patients with epithelial ovarian
cancer (EOC) are diagnosed at advanced stages 3 or 4, thus
implying spread throughout the peritoneal lining, paren-
chyma of the liver or pleura [4]. Treatment comprises a
combination of aggressive surgery plus cytotoxic chemo-
therapy [5]. Morbidity of treatment is considerable and
prognosis remains typically poor worldwide [1–3]. While
most patients respond to chemotherapy initially, the tumor
eventually becomes chemo-resistant which leads to relapse
[6], with an average disease progression free survival of
18 months [7] and a less than 30 % 5-year overall survival
rate [8]. By contrast, survival outcomes are generally good
for women diagnosed with non-epithelial ovarian cancer or
with EOC incidentally found at an early stage.
In the past three decades, our understanding of EOC has
been extended into its origin, classification and genetic
features. Studies on the characterization of metastasis of
ovarian cancer have led to the search for new biological
agents as part of therapeutic regimens. It is well known that
metastasis is associated with the invasive behaviors of
tumor cells in which cell membrane proteins, receptors and
extracellular matrix (ECM) proteins play important roles
[6]. As in other cancer types, cancer-associated proteases
are a crucial component in the regulation of these proteins
via hydrolysis, such as matrix metalloproteinase (MMP)2,
MMP7, MMP9 and urokinase plasminogen activator (uPA)
[9–11]. Recent studies have revealed that most kallikrein-
related peptidases (KLKs), a family of serine proteases, are
aberrantly expressed in cultured ovarian cancer cells and
patient specimens and may also play a role in cancer pro-
gression and in particular metastasis [12, 13]. In the fol-
lowing sections, we will focus on the pathogenesis of EOC,
the expression and function of KLKs in EOC, and the
challenges faced in the treatment of this cancer.
Pathogenesis of EOC
The normal ovary is covered by a single layer of flat or cuboidal
mesothelial cells. It has been hypothesized that EOCs originate
from these ovarian surface mesothelial cells. EOC has been
recognized as a heterogeneous and complex disease with
predominant serous, mucinous, clear cell, endometrial and
transitional cell types. However, recent studies have revealed
more genetic and molecular phenotypes that help us better
understand the clinical features as listed below.
Challenging the conventional hypothesis, recent patho-
logical studies have proposed that ovarian cancer might in
fact generate from seeding of cancer cells from the fallopian
tube to the ovary [14–17]. With combined analysis of
clinical, histopathological and genetic characteristics, Kur-
man and colleagues [17, 18] have proposed a two-pathway
model of this tumor. In particular, they accounted for the
difference of mutation frequencies of KRAS, BRAF and TP53
dividing EOC into two categories, Type-I and Type-II
tumors. Type-I tumors include serous, endometrioid,
mucinous, and clear cell types, but display low-grade nuclear
and architectural features, slow growth, and can be associ-
ated with well-defined benign and borderline (low malignant
potential) ovarian precursor lesions. Most often genetic
variations of Type-I tumors are KRAS and BRAF mutations
that activate the mitogen-activated protein kinase (MAPK)
signaling pathway [19–21]. Additionally, Type-I tumors are
more frequently found with mutations of ARID1A, ERBB2,
PTEN, CTNNB1 and PIKCA [22]. On the other hand, these
alterations are rarely seen in Type-II tumors which are fre-
quently ([80 % of cases) detected with mutations of TP53,
CCNE1 and chromosome instability [17, 22]. Type-II tumors
are rarely linked to benign or borderline ovarian precursor
lesions, but comprise almost all of high grade serous EOC,
with clinical features of a high growth rate, metastasis and a
less than 30 % 5-year patient survival rate [23]. Using inte-
grated genomic analyses, these Type-II tumours and in
particular the high grade serous EOCs are subdivided into
differentiated, immunoreactive, mesenchymal and prolifer-
ative groups due to their different gene signatures [24].
Relevant to ovarian cancer metastasis, and critically due
to the lack of an anatomical barrier around the ovary and
exposure to the peritoneal space, individual EOC cells or
small cell clusters are shed from the primary tumor into the
abdominal cavity. These tumor cells adhere to and disrupt
the peritoneal mesothelial cells, exposing the Type-I/III
collagen-rich ECM underneath the peritoneal membrane.
The EOC cells adhere strongly to the exposed ECM, in
comparison to the mesothelial cells which adhere more
strongly to the interstitial Type-I collagen [25]. Another
clinical feature indicative of a poor prognosis for patients
with this malignancy, in particular high grade serous EOC,
is the formation of ascites fluid [26]. More than 70 % of
EOC patients, in particular those with Type-II tumors,
present with a pool of fluid in their abdominal cavity
(ascites/effusions) harboring a population of tumor cells
[26]. This is due to obstruction of lymphatic vessels by
implanted tumor, preventing the outflow of fluid that leaks
from disorganized tumor vessels and thus accumulating
ascites [27]. In this scenario, patients with the aggressive
Type-II tumors, in particular high grade serous EOCs, not
only have metastatic tumors that grow in solid stromal
matrices but also a cell population suspended in the ascites
fluid [4, 6, 28]. Similar to the tumor cells in the solid
matrices of the metastatic sites, the EOC cells derived from
ascites fluid are resistant to various therapeutic regimes
[28]. In particular, a recent study demonstrated that a
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subpopulation of EOC cells expressing CA125, EpCAM
and STAT3, is able to grow as three dimensional (3D)
suspension spheroids or multicellular aggregates (MCAs)
that are tumorigenic and resistant to chemo-treatment [29].
These CA125, EpCAM and STAT3 positive ascitic EOC
cells are the source of peritoneal adhesions leading to a
poor outcome of women diagnosed with this disease.
However, the mechanisms underlying metastasis to the
peritoneal membrane remain to be elucidated.
Kallikrein-related peptidases (KLKs)
The kallikrein locus, with 15 members in this family, spans
approximately 265 kb on chromosome 19q13.3-13.4
forming the largest continuous cluster of human proteases
(Fig. 1a) [30–34]. Each KLK gene contains 50 and 30-
untranslated region, 4 introns and 5 exons encoding each of
the KLKs (Fig. 1a, b). The KLKs are synthesized as pre-
pro-peptidases, with the pre-signal peptide crucial for
secretion of these enzymes (Fig. 1b). Cleavage of the pro-
peptide is required for activation to the mature enzyme
with appropriate conformation of the catalytic triad, histi-
dine (His), aspartate (Asp) and serine (Ser). Members of
the KLK family have trypsin or chymotrypsin-like sub-
strate specificity. KLK1, KLK2, KLK4–KLK6, and
KLK10–KLK15 have trypsin-like specificity for cleavage
after argine and lysine residues [35, 36]. KLK15 also has
trypsin-like specificity but cleaves after a glutamate residue
[37]. On the other hand, KLK3 and KLK7 display
chymotrypsin-like specificity for tyrosine, leucine, and
phenylalanine residues [13, 38]. Given this specificity and
that most KLKs require an enzyme with trypsin-like
specificity for activation, it is not surprising that KLK
activation cascades can occur in many tissues [13, 39, 40].
It has also been documented that KLKs can be activated by
other proteases with a recent biochemical study showing
that matrix MMP20 cleaves pro-KLK1–4, pro-KLK6, pro-
KLK7, pro-KLK9, pro-KLK11 and pro-KLK15 [41].
Like other serine proteases, once KLKs are activated,
their proteolytic action is irreversible and controlled by
endogenous inhibitors [42]. The endogenous inhibitors
targeting distinct KLKs have been identified, such as zinc
ions, Kazal-type inhibitors and a2-microglobulin [43, 44].
Recently, the naturally occurring 14 residue long cyclic
sunflower trypsin inhibitor (SFTI of the Bowman-Birk
family) was redesigned to inhibit specific kallikreins using
a combination of molecular modeling and matrix substrate
screening [45]. SFTI–FCQR selectively blocks the prote-
olytic activity of KLK4 and reduces the activity of the
proteinase activator receptor (PAR)2, a KLK4 substrate, in
a cell-based assay [45]. In addition, the SFTI–FCQR Asn14
variant can also inhibit KLK4, and importantly, this variant
displayed bioactivity in an in vivo mouse model [46].
Using a similar approach, SFTI–WCTF was selected to
potently inhibit KLK7 proteolytic activity at a nanomolar
concentration [47].
From a clinically relevant aspect, tissue-specific asso-
ciation of KLKs has been identified. For instance, KLK2,
prostate-specific antigen (PSA)/KLK3, KLK4 and KLK11
Fig. 1 Genes and exon/intron organization of kallikrein-related
peptidases. a Location of the KLK locus at chromosome 19q13.3-
13.4. Schematic representation of the interval between D19S425 and
D193418. The KLK locus is located proximal to D19S418. The
position of the 15 kallikrein encoding genes on the KLK locus is
marked. KLK1, KLK15, to KLK14 are transcribed telomere to
centromere, whereas KLK2 and KLK3 are transcribed in the opposite
direction. KLKs highlighted in dark red are representative of their
aberrant expression associated with poor outcome for ovarian cancer
patients, while green indicates an association with favorable patient
outcome. b Schematic showing the organization of 50-untranslated
region (50-UTR), coding region (exons and introns), and 30-UTR of
KLKs (top panel) and KLK protein structure (bottom panel).
Catalytic triad, His, Asp and Ser, as indicated
Clin Exp Metastasis (2014) 31:135–147 137
123
are expressed at higher levels in prostate tissue extracts and
seminal fluid, KLK5–11 in skin, and KLK6 and KLK8 in
cerebrospinal fluid [48] where the activation cascades
noted above can occur. It has become evident that
expression of many KLKs is regulated by steroid hormones
in a tissue-specific manner, such as KLK2, PSA/KLK3 and
KLK4 by androgen in prostate and breast cancer cells, and
KLK4 by estrogen in endometrial and ovarian cancer cells
[49–52].
Patho-physiological roles of KLKs
It has been well documented that KLK enzymes have
extracellular hydrolysis activities, such as activating and/or
degrading their substrates, including growth factors, ECM
proteins, other cancer-associated proteases, cell membrane
bound receptors and adhesion proteins. Just as KLK family
members have a diverse tissue/organ expression profile,
they also have a wide range of physiological functions. For
example, KLK1 has a role in the cardiovascular system via
cleavage of the low molecular weight kininogen to gener-
ate bradykinin, which stimulates its receptor, the bradyki-
nin receptor 2 [53]. KLK4 is involved in the remodeling of
the organic matrix and disruption of intercellular junctions
in tooth development via hydrolysis of enamelin [54, 55]
and amelogenin [56]. KLK4 can also activate pro-meprin b
and may have a role in keratinocyte migration in skin [57].
In addition to KLK4, a recent study has identified that
KLK5 and KLK8 cleave meprins, suggesting their role in
this process, and interestingly, KLK5 can also cleave the
other subunit of the family, pro-meprin a [58]. KLK5 and
KLK7 are involved in keratinization, stratum corneum
formation, turnover and desquamation of the skin, via
degradation of the cell adhesion glycoproteins, corne-
odesmosin and plakoglobin [59–61]. These two enzymes
have also been localized to numerous other tissues, and
their function via hydrolysis to degrade cell membrane
bound adhesion glycoproteins, has been found in these
organs. KLK6 can hydrolyze the amyloid precursor pro-
tein, which is important in the deposition of amyloid pla-
ques and regulation of neural plasticity [62–64]. KLK6 also
cleaves myelin basic protein in oligodendrocytes and
Schwann cells in the central nervous system in a manner
that is related to demyelinating diseases, such as multiple
sclerosis [65]. These studies provide evidence that KLK
enzymes play a role in diverse patho-physiological pro-
cesses in human.
PSA/KLK3, a member of KLK gene family, is a well
established and clinically-used biomarker for prostate
cancer [66]. Recent studies have associated the function of
KLKs with the progression of human cancer. Both KLK2
and PSA/KLK3 degrade insulin growth factor binding
protein (IGFBP)2, IGFBP3, IGFBP4 and IGFBP 5, thereby
releasing the insulin growth factor-1 (IGF1) and regulating
the survival and proliferation of both normal and cancerous
prostate cells [67, 68]. KLK4 can activate other enzymatic
pathways, e.g. MMP [69], pro-uPA to uPAwhich binds to
its receptor uPAR [70]. Interestingly, however, uPAR can
be cleaved by KLK4 leading to inactivation of this receptor
[70]. Hence, KLK4 is an important mediator of the uPA/
uPAR axis which is known to have an important role in
cancer invasion [71, 72]. A recent study shown that KLK7
cleaves proMMP9 generating an active MMP9 fragement
but not by other proteases [69]. More recent studies have
demonstrated that several KLKs activate a family of
G-protein coupled receptors, PARs. For example, PAR1 is
activated by KLK1, KLK4–6 and KLK14, PAR2 by KLK2,
KLK4–6 and KLK14, and PAR4 by KLK1 and KLK6,
leading to the activation of downstream signaling pathways
[73–75]. We and others have shown that cleavage of PAR2
by KLK4 activates the MAPK signaling pathway leading to
the growth of prostate and colon cancer cells [76, 77].
KLK7 induces shedding of the cell adhesion protein
E-Cadherin, uPAR and ECM protein, vitronectin (VN)
break-down promoting an enhanced cell proliferation,
migration and invasion in pancreatic cancer cells [78, 79].
Together, these findings suggest important roles of KLKs
not only in normal physiological processes but also in
disorders such as, cancer.
Expression of KLKs in ovarian cancer
In the last decades, numerous studies have determined the
aberrant expression of members of the KLK family in
ovarian cancer [80–82]. Different groups, including ours,
have reported that the majority of the KLKs (KLK4–11,
KLK13–K15) are aberrantly expressed in ovarian cancer-
ous, compared to normal and benign tissues [12, 80, 81]. It
has been reported that at the transcriptional level, KLK4–8,
KLK10 and KLK14 are highly expressed in ovarian cancer
tissues. Importantly, unbiased gene microarray analyses
demonstrated an up-regulated transcription of KLK5–8 and
KLK10 in EOC [83, 84]. High protein levels of KLK4–7
and KLK10 have been found in ovarian cancer tissues,
while KLK5–8, KLK10, KLK11, KLK13 and KLK14 were
found in ascites fluid from ovarian cancer patients as
reviewed [81, 85, 86]. Interestingly, KLK6 and KLK10
have shown a strong potential as clinical serum biomarkers
for this cancer [81].
Of further clinical relevance, high mRNA and/or protein
levels of KLK4–7, KLK10 and KLK15 are associated with
shorter progression-free and overall survival time of patients
[87–92]. Significantly, the up-regulated expression of
KLK4–7, KLK10 and KLK15 is associated with high grade
138 Clin Exp Metastasis (2014) 31:135–147
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and late stage disease, belonging to the more aggressive
Type-II tumors [87–92]. Interestingly, KLK5–7 expression
in EOC tissues displayed a closer association with a larger
remaining tumor following surgery, higher grade and later
stage disease than CA125 [93], the currently used biomarker
for women with this cancer. A recent study demonstrated
that the expression of KLK6 in stromal cells was associated
with aggressiveness of this disease, suggesting its role in the
EOC microenvironment [94]. High serum levels of KLK5
[95, 96], KLK6 [97, 98] and KLK10 [99] were associated
with poor outcome in women with EOC, suggesting their
potential as alternative biomarkers for this malignancy.
KLK6–8 and KLK10 have been found to be more specific
than KLK4, KLK5, KLK11, KLK14 and KLK15 in EOC
[100] in differentiating between benign and other malignant
secretions in ascites and pleural effusion fluid. In addition,
we and others have reported that high tumor levels of KLK4
and KLK7 were associated with chemoresistance in patients
with this cancer [101–103]. On the other hand, levels of
KLK8, KLK9, KLK11, KLK13 and KLK14 in tumor tissues
were higher in early stage disease, when optimal debulking
surgery had been performed, and in those patients who
responded to chemotherapy and had a long survival time [91,
104–106]. Our studies, and those from others, showed that
KLK4–8 and KLK10 are expressed at high levels in EOC, in
particular in high grade serous EOC [52, 89, 107–109]. A
strong correlation within the cluster of kallikreins, KLK5–8,
KLK10 and KLK11 in EOC tissue samples has been
reported [110] suggesting their co-expression in this disease.
Recent studies using genome-wide microRNA (miRNA)
profiling approaches have demonstrated the association
between expression of miRNAs with pathogenesis, and
their potential assistance in diagnosis and prognosis of
ovarian cancer. miRNAs have been shown as tumor sup-
pressors or oncogenes, and can also target different cell
signaling pathways [111]. For example, let-7a-2 targets
KRAS and IL6 functioning as a tumor suppressor, while
miR-21 regulates PTEN as an oncogene. Recent bioinfor-
matics analyses have predicted the potential regulation of
KLK peptidases by multiple miRNAs [112]. To confirm
these findings, White et al. have shown that transfection of
let-7f, miR-224, or miR-516a in EOC OVCAR-3 cells
reduced expression of KLK10 at both mRNA and protein
levels, and cell proliferation [112]. In addition, transfection
of let-7f miRNA significantly decreased KLK6 and KLK10
secretion into conditioned media, indicating that one single
miRNA targets multiple KLKs [113]. These studies pro-
vide evidence that KLK expression is regulated by miR-
NAs which have a role in post-transcriptional regulation of
KLK peptidases.
Together, differential expression of KLKs not only has
potential as EOC biomarkers, but may indicate a critical role
of these peptidases in the ovarian cancer microenvironment
promoting progression and chemo-resistant metastasis,
especially in the aggressive Type-II tumors.
Functions of KLKs in ovarian cancer metastases
KLKs enhance EOC multicellular aggregation
in 3-dimensional (3D) microenvironments
As KLK4 and KLK7 are up-regulated in EOC cells and
tumor tissue samples, with high levels associated with poor
outcome in women with this disease [87, 102???], we over-
expressed these peptidases in SKOV3 EOC cells to deter-
mine their function. We found a reduced migration of
SKOV3 cells stably over-expressing KLK4 or KLK7, but no
significant changes in cell proliferation in conventional
2-dimensional (2D) monolayer cultures. To investigate the
role of these enzymes in the ovarian tumor microenviron-
ment (Fig. 2a) [4, 28], we established a 3-dimensional (3D)-
suspension culture (Fig. 2b) to mimic the ascites fluid seen
in patients [114]. It is known that homotypic cell adhesion
promotes cell survival by forming MCAs in the ascitic fluid
suspension microenvironment, and we observed the for-
mation of compact MCAs in KLK4-expressing SKOV3
cells, as did SKOV3 cells treated with recombinant active
KLK4 [103]. MCA formation was reduced by treatment
with a KLK4 blocking antibody or the selective active-site
KLK4 sunflower trypsin inhibitor (SFTI-FCQR), further
supporting the role of this peptidase in EOC. KLK4-
expressing SKOV3 cells had high levels of the KLK4 sub-
strate, uPA, particularly in 3D-suspension, and high levels of
both KLK4 and uPA were observed in patient cells taken
from ascites [103]. Lipocalin 2, also named neutrophil gel-
atinase-associated lipocalin, has been linked to an EOC
phenotype [115], and we showed its induction in KLK4-
expressing SKOV3 cells and further up-regulation in the 3D-
suspension microenvironment [114].
Similar observations were also made in KLK7-
expressing SKOV3 cells cultured in 3D-suspension [102]
and in the endogenous KLK7 expressing OVCA432 cells
(Fig. 2b, left panel). Different from KLK4, however,
increased levels of a5/b1 integrins and enhanced adhesion
to FN and VN, which was inhibited with a b1 integrin
blocking antibody, were observed. Blocking MCA using
antibodies against KLK7, a5b1 and b1 integrins confirmed
the involvement of KLK7 and integrin-regulated cell
adhesion. Importantly, these MCAs invade into a mono-
layer of peritoneal mesothelial LP9 cells and form cancer
cell foci (Fig. 2b, mid panel). We also found that EOC
cells derived from ascites fluid expressed higher levels of
KLK7 and a5b1 integrin compared to their matched pri-
mary tumor cells [102]. Our findings suggest a mechanism
for the association of high KLK7 levels with poor
Clin Exp Metastasis (2014) 31:135–147 139
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prognosis for serous EOC patients by promotion of peri-
toneal dissemination and invasion via increased MCA
formation and a5b1 integrin-mediated cell adhesion. These
findings suggest a role of KLKs in EOC metastasis due to
the formation of MCA and peritoneal invasion, but the
underlying mechanisms differ as KLK4 acts via uPA whilst
KLK7 induced integrin-associated pathways.
As noted as above, an in vitro biochemical feature of the
members in the KLK family is an enzymatic cascade
between different KLKs [116, 117]; KLK4 activates pro-
KLK6 and proKLK5, KLK5 auto-activates and activates
proKLK6 and proKLK7, KLK6 auto-activates and partially
activates proKLK5 (Fig. 3). Importantly, parallel expres-
sion of these KLKs has been shown in EOC [12], indi-
cating their interacting roles in this disease (Fig. 3). A
previous study demonstrated that simultaneous over-
expression of KLK4, KLK5, KLK6 and KLK7 (KLK4-7)
in OV-MZ-6 EOC cells significantly increased their inva-
sive behavior in an in vitro transwell Matrigel assay [118].
These KLK4–7 expressing OV-MZ-6 cells increased tumor
growth in an animal model compared to OV-MZ-6 cells
expressing the single KLK4, KLK5, KLK6 or KLK7, or
vector controls. To explore the underlying mechanism, our
group has recently reported that KLK4–7 expressing OV-
MZ-6 cells had reduced levels of a5b1 and avb3 integrins,
leading to reduced adhesion to the ECM proteins FN and
VN [119].
To understand the crucial mechanism underlying the
interaction between EOC cells and their extracellular
microenvironment, we have employed a bioengineered
hydrogel platform [120] (Fig. 3c). This 3D platform com-
prises synthetic protease-sensitive hydrogels that are
Fig. 2 Cell culture platforms to mimic EOC metastasis. a Schematic
diagram showing potential roles of KLKs in EOC peritoneal
dissemination. b Top left panel, 3D-suspension cultures to mimic
the EOC cells growing in the ascites fluid microenvironment. Top
right panel, MCAs invading into a monolayer of mesothelial cells to
mimic peritoneal invasion. Bottom left panel, MCAs formed by
OVCA432 cells stained with anti-KLK7 and AlexaFluor488 (green),
F-actin stained with AlexaFluor568 phalloidin (red), nuclei stained
with 40,6-diamidino-2-phenylindole (DAPI, blue). Bottom right panel,
invasion into mesothelial cell monolayer by KLK7-expressing
SKOV3 cell (SKOV3-K7) MCAs stained with anti-E-Cadherin
(Ecad) and AlexaFluor488 (green), F-actin stained with AlexaFlu-
or568 phalloidin (red), nuclei stained with DAPI (blue). c Top panel,
schematic showing ovarian cancer cells embedded and cultured in 3D
bioengineered hydrogels, alone (left) and sheet (right) co-culture with
mesothelial cells. Bottom panel: KLK4–7-expressing OV-MZ-6 cells
grown in the above models. F-actin filaments stained with rhodamine-
415 conjugated phalloidin (red) and imaged by confocal laser
scanning microscopy. Scale bars as indicated. With permission from
Walter de Gruyter to use the elements of the figure in the published
book ‘Kallikrein-related peptidases’ [114]
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formed from peptide-functionalized polyethylene glycol
macromolecules via a factor XIII-catalysed reaction, sim-
ilar to the fibrinogen cross-linking that occurs during nat-
ural fibrin coagulation [121, 122]. Interestingly, over-
expression of KLK4–7 did not alter the proliferation rate of
OV-MZ-6 EOC cells when cultured as conventional 2D
monolayers [118]. However, KLK4–7 expressing OV-MZ-
6 cells formed more and larger spheroids when cultured in
3D bioengineered matrices [114, 123]. In particular, a
much higher growth rate of KLK4–7 expressing spheroids
was seen when they were co-cultured with mesothelial
cells, implying their growth-promoting effect on EOC cells
[114]. Together, we have demonstrated that KLK pepti-
dases promoted EOC cell survival, MCA formation,
adhesion to ECM proteins and invasion into the peritoneal
microenvironment, ultimately leading to metastasis.
Chemoresistance is mediated by KLK proteases in EOC
Chemoresistance is a major obstacle to overcome for pro-
longing the survival time of women with EOC. A previous
study showed that high levels of KLK10 (also known as the
normal epithelial cell-specific 1, NES1) in tumor tissue
predicted tamoxifen resistance in breast cancer patients
[124]. An early study showed that expression of KLK4 in
ovarian cancer tissues is associated with resistance to a first
line, clinically-used chemo-agent paclitaxel in EOC
patients [125]. We have recently confirmed this finding
[103] and also demonstrated that high levels of KLK7 in
tumor tissues are associated with chemoresistance in EOC
patients [102]. It has been documented that MCAs, repre-
senting a 3D architecture, are more resistant than 2D
monolayer cells [126], and compact MCAs are less
responsive to various treatments, including chemothera-
pies, than scattered and small MCAs [127]. In in vitro
studies, we observed that KLK4, but not KLK7-expressing
SKOV3 cells are more resistant to cisplatin in 2D mono-
layer cultures [102, 103]. However, MCAs formed by
either KLK4 or KLK7 expressing SKOV3 cells are less
responsive to paclitaxel than the vector and native control
cells when cultured in 3D-suspension as MCAs. Interest-
ingly, adding the KLK4 selective SFTI–FCQR not only
reduced the compaction of KLK4-expressing MCAs but
importantly increased their response to paclitaxel to a
greater degree than the general serine protease inhibitor,
aprotinin [103]. Lipocalin 2, has been associated with
chemoresistance [128, 129] and is up-regulated in KLK4
expressing SKOV3 cells cultured as MCAs in 3D suspen-
sion [114]. Furthermore, KLK4–7 expressing OV-MZ-6
cells were less responsive to paclitaxel, but not carboplatin,
in both 2D monolayers and 3D bioengineered matrices
[119]. In search of the underlying mechanism, we reported
that the reduced paclitaxel response is independent of
MAPK signaling [119]. Interestingly, the levels of a5b1
and avb3 integrins decreased in KLK4–7-expressing OV-
MZ-6 cells, but adding paclitaxel increased the level of a5
integrin, suggesting its role in paclitaxel resistance induced
by these four KLKs [114, 119]. These data imply the
potential of inhibition of KLK action as part of a combined
therapeutic approach for EOC patients, especially those
with high KLK levels in their tumors.
Proteolytic functions of KLKs in ovarian cancer
metastasis
In vitro biochemical studies demonstrated that KLK
enzymes function via extracellular hydrolysis or proteo-
lytic activity, such as cleavage of cell–cell adhesion pro-
teins, membrane bound proteins and receptors, cytokines
and growth factors, ECM proteins, and proteases including
KLKs. For example, KLK4–7 regulate the break-down of
the ECM proteins fibronectin (FN), VN, laminin and Type-
I and IV collagens [63, 130–134]. All these proteins form
part of the ECM that underlies the mesothelial cell layer
lining the abdominal cavity which is the most common
EOC metastatic site [135, 136]. The cleaved ECM products
can contribute to an altered cellular phenotype and cell
function, promoting migration and invasion of EOC cells
leading to the establishment of metastasis [137–139]. It has
been reported that MMP2 cleaves FN and VN into small
fragments and increases binding of EOC cells to these
fragments and their receptors a5b1 and a3b1 integrins
promoting peritoneal adhesion and invasion [136]. It has
also been documented that FN is a substrate of KLK7 [134]
and we showed that KLK7 over-expression in SKOV3
EOC cells induced their adhesion to this substrate and the
level of its receptor a5b1 integrins increased [102]. In
addition to the ECM components, proteases can also be
substrates of KLK enzymes. KLK4 can cleave uPA, to
generate its active form, and also its receptor uPAR [70,
140], both known to be induced in EOC cells in the ascites
fluid [141], and associated with chemoresistance and poor
Fig. 3 Schematic diagram showing the biochemical activation cas-
cade of KLK4, KLK5, KLK6 and KLK7 (dashed lines) and their roles
in different aspects of ovarian cancer metastasis (continuous lines).
ECM extracellular matrix
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prognosis in patients with EOC [142, 143]. KLK7 can
cleave the cytokine interleukin (IL)-1b converting it to its
active form [144] which can modify the morphology of
mesothelial cells, allowing EOC cells to invade into the
ECM beneath the peritoneal membrane [145]. KLK6 [146]
and KLK7 [78] cleave the cell adhesion protein E-cadherin
generating shed fragments which are at a high level in
metastatic EOC and ascites [137]. Interestingly, loss of
E-cadherin has been associated with EOC progression,
parallel to MMP9 [11] which is also a substrate of KLK7
[69]. These data generated from patient samples in clinical
studies, along with their biochemical activity, implicate
KLKs in the progression and chemoresistance of metastatic
EOC.
Non-proteolytic functions of KLKs in ovarian cancer
Although KLK peptidases function via extracellular
hydrolysis to exhibit their enzymatic activity, recent stud-
ies have shown their non-proteolytic function in ovarian
cancer both in vitro and in vivo. In the KLK gene family,
more than 80 splicing variant transcripts have been iden-
tified [147, 148]. We have previously reported the simul-
taneous expression of the wild type transcript encoding the
full-length KLK7 and the mRNA variant for an N-terminal
truncated KLK7–181 protein in EOC but not in normal
ovarian epithelial cells [107]. In later functional studies, we
observed that similarly to wild type KLK7, KLK7–181-
expressing SKOV3 cells showed increased adhesion to the
ECM proteins FN and VN, formed compact MCAs and
were more resistant to paclitaxel treatment, suggesting a
role of this KLK7–181 variant which is not enzymatically
active [102]. We have also found that active KLK4 enzyme
treated SKOV3 cells formed compact spheroids that were
larger than those treated with the non-active mutant KLK4
(serine to alanine mutation at catalytic triad) which in turn
were slightly larger than those seen for vector and native
control cells [103]. These data indicate that the action of
KLK4 in MCA formation involves both proteolytic and
non-proteolytic effects. In addition, KLK10 (NES1) was
identified from breast cancer cells but is down-regulated in
the progression of EOC [149]. Over-expression of KLK10
in ES2 EOC cells reduced their anchorage-independent
growth in vitro and caused a smaller tumor burden in an
animal model compared to vector controls [150]. Adding
recombinant KLK10 protein into cultures confirmed these
findings, supporting its role as a tumor suppressor in EOC
progression both in vitro and in vivo. However, the
recombinant KLK10 added lacked catalytic activity, indi-
cating a non-proteolytic function in the progression of this
disease. These findings are consistent with an earlier study
in which two blocking antibodies against PSA/KLK3, one
inhibiting the enzymatic activity and the other one not
affecting the catalytic activity, both inhibited the biological
function of this KLK, suggesting that PSA also has an
alternative action via protein–protein interactions [151].
In summary, we have reviewed recent studies on the role
of kallikrein peptidases in ovarian cancer progression and
resistance to chemotherapy. Importantly, our findings and
those of others have provided evidence that both 3D-sus-
pension models and bioengineered matrices can success-
fully be used as in vitro 3D platforms for research into the
functional roles of KLK enzymes on ovarian cancer
metastasis and chemoresistance.
Future directions
For the past decade, our understanding of ovarian cancer
progression and chemo-resistant metastasis has been stea-
dily increasing, including our knowledge of the roles of
cancer-associated proteases, such as KLKs. To investigate
the roles of KLKs in the development, progression, and in
particular the chemo-resistant metastasis of ovarian tumors,
we have developed in vitro cell culture platforms that
closely mimic the in vivo microenvironment. However, we
still face challenges to improve these platforms to examine
the function of KLK proteases specifically in different
EOC microenvironments. In addition, some KLK enzymes
have shown potential as pharmaceutical targets while other
KLKs may have potential as part of combined therapeutic
approaches. Of note, recent studies have shown the
potential of synthetic small inhibitors to target individual
KLK enzymes at in vitro biochemical and cellular levels
[43, 44, 152]. We are still at an early stage testing the anti-
metastatic potential of KLK inhibitors using these 3D
platforms, and more effort is needed in developing these
assays for application to patient derived tumor cells. Fur-
thermore, how interactions in vitro between postulated
proteolytic cascades involving different KLK proteases
occurs in biological tissues and other related factors and/or
contributors occur remains largely unknown. Therefore, we
endeavor to identify the biological substrates of the ovarian
cancer associated KLK peptidases and their regulated sig-
naling networks in order to identify the underlying
molecular mechanisms and molecular targets. Our
increasing knowledge will enable further efforts in search
of the most effective approaches to target KLK action in
the tumor microenvironment, improving the survival time
of women with this cancer as well as their quality of life.
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